Literature DB >> 18021521

Quality indicators, guidelines and outcome measures in ankylosing spondylitis.

J Zochling1, J Braun.   

Abstract

The challenge of managing knowledge is a difficult one, and it is no longer enough simply to conduct clinical trials. Quality of care requires the incorporation of research knowledge into clinical practice. As our knowledge of the chronic inflammatory rheumatic disease ankylosing spondylitis (AS) has grown, evidence-based recommendations for the early diagnosis and management of AS and scientifically-derived outcome measures have been developed to aid the clinician at the point of care. Some of these, including the ASAS/EULAR recommendations for the management of AS, are now being validated in national and international studies. This article discusses existing recommendations and the need for specific quality indicators in the field of AS.

Entities:  

Mesh:

Year:  2007        PMID: 18021521

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

1.  Evaluation of the Iranian versions of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Patient Acceptable Symptom State (PASS) in patients with ankylosing spondylitis.

Authors:  Katayoon Bidad; Sasan Fallahi; Mahdi Mahmoudi; Ahmadreza Jamshidi; Elham Farhadi; Alipasha Meysamie; Mohammad Hossein Nicknam
Journal:  Rheumatol Int       Date:  2011-11-20       Impact factor: 2.631

2.  Efficacy of SLZ and MTX (alone or combination) on the treatment of active sacroiliitis in early AS.

Authors:  Yasemin Kabasakal; Gul Kitapcioglu; Figen Yargucu; Ali Taylan; Mehmet Argin; Gurbuz Gumusdis
Journal:  Rheumatol Int       Date:  2009-07-11       Impact factor: 2.631

3.  Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis.

Authors:  Hatice Bodur; Filiz Eser; Sefika Konca; Serpil Arikan
Journal:  Rheumatol Int       Date:  2008-08-21       Impact factor: 2.631

4.  Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.

Authors:  H Marzo-Ortega; J Sieper; A Kivitz; R Blanco; M Cohen; R Martin; A Readie; H B Richards; B Porter
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-06-07       Impact factor: 4.794

5.  A retrospective study of alendronate for the treatment of ankylosing spondylitis.

Authors:  Gang Li; Chang-An Lv; Li Tian; Lian-Jin Jin; Wei Zhao
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

6.  Proteomic analysis of human synovial fluid reveals potential diagnostic biomarkers for ankylosing spondylitis.

Authors:  Ji-Hyun Lee; Jae Hun Jung; Jeesoo Kim; Won-Ki Baek; Jinseol Rhee; Tae-Hwan Kim; Sang-Hyon Kim; Kwang Pyo Kim; Chang-Nam Son; Jong-Seo Kim
Journal:  Clin Proteomics       Date:  2020-06-01       Impact factor: 3.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.